MCHP — Microchip Technology Incorporated

The August 6, 2026 earnings report is the dominant driver: revenue of $1.485 billion was up 38% YoY, non-GAAP EPS of $0.76 beat consensus near $0.70, and September-quarter guidance of $1.589-$1.618 billion came in well above expectations. Analysts remain heavily positive — 30 Buy ratings, 14 Holds, 0 Sells — and the recent average price target of $99.50 implies meaningful upside from $75.49, even though the stock's price action has lagged the improving fundamentals.

The data shows a clear cyclical inflection, not a one-quarter blip. Revenue peaked at $2.254B in September 2023, collapsed to a $970.5M trough in March 2025, and has since risen for five consecutive quarters: $1.0755B, $1.1404B, $1.186B, $1.3112B, and $1.4847B in June 2026 — the last up 13.2% sequentially and 38% YoY. GAAP operating margin followed the same arc, going from -10.3% in March 2025 to 3.0% in June 2025, then 8.3%, 12.8%, 16.1%, and 22.7% by June 2026. Net income swung from losses in late 2024/early 2025 to $229.8 million in the June 2026 quarter. This is an inventory-correction recovery now feeding through utilization, margins, and cash flow.

On trailing GAAP numbers MCHP looks expensive — P/E of 104.6x and P/S of 8.0x — but that is distorted by a trough TTM EPS of just $0.831. Using FY27 consensus EPS of $3.641, the forward P/E is approximately 20.7x, which is much more reasonable for a high-margin semiconductor franchise in the early/mid stages of a recovery. Forward P/S on FY27 revenue of ~$6.397B is about 6.4x, roughly in line with the 5-year average of 6.25x. The deterministic score labels valuation 'Rich vs. its own history,' but that is largely a cyclical-trailing-earnings artifact; on forward earnings the stock is fairly valued, not egregiously expensive.

At $75.49, the market is pricing in a continued recovery but not a full-blow bull case. 20.7x forward EPS is not demanding if MCHP hits its September-quarter guidance of $0.91-$0.95 EPS and raises as the year progresses. The downside scenario would be a re-rating to 18x forward EPS, which would put the stock near $65.50, so the key swing factor is whether the next two earnings reports confirm that margins and revenue keep climbing. Right now, price is lagging earnings because the market is still weighting macro/auto risk heavily; if the earnings momentum continues, the stock should re-rate upward.

As of 2026-08-27, RSI stood at 44.26, which is neutral rather than oversold or overbought. Price was -2.62% below the 20-day SMA, -8.65% below the 50-day SMA, and -1.73% below the 200-day SMA. That is a consolidating, range-bound technical picture: the stock is no longer collapsing, but it has not yet confirmed a new uptrend by reclaiming its moving averages. The proximity to the 200-day SMA makes that level a key battleground; a decisive reclaim would improve the entry signal, while another rejection would suggest continued sideways churn.

• Inventory normalization across industrial and automotive end-markets is the primary tailwind, driving utilization and gross margin recovery after the post-pandemic glut.
• Higher-for-longer interest rates remain a headwind for broad industrial capex and auto demand, which are MCHP's larger end-markets.
• Data center, aerospace, and defense demand is providing a strong offset and broad-based bookings improvement.
• Semiconductor cyclicality amplifies the swing: factory utilization recovery is converting operating leverage directly into margin expansion.
• Balance-sheet deleveraging is reducing net debt and improving the company's resilience to a potentially slower macro environment.

• FQ2 2027 earnings due November 5, 2026 — guidance is already strong at $1.589-$1.618B revenue and $0.91-$0.95 EPS, and any raise on top of that would be a major positive.
• Continued gross and operating margin expansion toward the 38.5%-39.5% operating-margin band as utilization improves.
• Further debt reduction and capital return; MCHP declared a $0.455 quarterly dividend payable September 9, 2026.
• Potential analyst target upgrades as forward estimates catch up to the visible sequential revenue acceleration.

• The auto and industrial recovery could stall if interest rates stay high or macro capex sentiment deteriorates again.
• Inventory correction could re-emerge in some end-markets, interrupting the current six-quarter sequential revenue growth streak.
• Execution risk on the aggressive margin guidance — if utilization or pricing disappoints, the operating margin recovery could slow.
• With ~$5.36B in long-term debt and a beta of 1.74, MCHP is financially and operationally cyclical; a forward de-rating to 18x EPS would meaningfully undercut the current price.

As of 2026-08-27, MCHP is an attractive cyclical recovery candidate: revenue, margins, FCF, and backlog are inflecting upward, the balance sheet is improving, and the stock is only about 20.7x forward EPS despite a trailing P/E above 100x that looks scary at first glance. The main risk is that a macro-induced stall in autos/industrial interrupts the recovery before the market fully re-rates the stock. For an investor who can tolerate cyclicality and wants exposure to a proven franchise in the middle of a demand upcycle, the risk/reward leans positive into the November 2026 print.

I applied a 22.5x forward P/E multiple to FY27 consensus EPS of $3.641, giving $81.92. The 22.5x multiple reflects MCHP's recovering gross/operating margins, strong FCF generation, improving balance sheet, and a visible cyclical upturn, while avoiding the full-bull 27-30x multiple embedded in the highest analyst targets.